FDA Approves Groundbreaking Pancreatic Cancer Drug 'Daraxonarasib' That Doubles Patient Survival Time

Pancreatic cancer has long stood as one of the most aggressive and deadliest forms of malignancies, often diagnosed late and plagued by the severe, painful side effects of conventional chemotherapy. However, decades of tireless research have finally yielded a monumental breakthrough in modern medicine. The United States Food and Drug Administration (FDA) has officially approved a revolutionary new targeted medication called daraxonarasib